Results 211 to 220 of about 45,688 (235)

FGFR2 inhibition could suppress spermatogenesis.

Journal of Clinical Oncology, 2020
e15659 Background: The incidence of cancer among the people of reproductive age is constantly increasing. Although FGF2/FGFR2 expression in the male reproductive tract has been reported, there is no evidence of the impact of FGFRs inhibitors on sperm function.
Ilya Tsimafeyeu, Nataliya Lapina, Mikhail Byakhov, Nadezhda Dragun, Evgenia Gavrilova, Anastasia Skorobogatova, Kira Stosman, Marina Melikhova, Olga Vakunenkova, Vadim Kashuro, Mikhail Rozhko, Sergei Tjulandin   +11 more
openaire   +1 more source

Clustering of FGFR2 gene mutations inpatients with Pfeiffer and Crouzon syndromes (FGFR2-associated craniosynostoses)

Cytogenetic and Genome Research, 2000
A cohort of 36 unrelated German patients with craniosynostosis syndromes of the Crouzon and Pfeiffer type were analyzed for FGFR mutations. Mutations in FGFR2 were identified in 25 Crouzon and 5 Pfeiffer syndrome patients, whereas no sequence alterations were found in the remaining patients, even after screening of the relevant parts of FGFR1, FGFR3 ...
W, Kress, H, Collmann, M, Büsse, B, Halliger-Keller, C R, Mueller   +4 more
openaire   +2 more sources

Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma

Journal of Dermatological Science, 2008
[No abstract available]
SKROZA, Nevena, Sabrina Rotolo, CECCARELLI, SIMONA, ROMANO, Ferdinando, Daniele Innocenzi, FRATI, Luigi, ANGELONI, Antonio, MARCHESE, Cinzia   +7 more
openaire   +3 more sources

Mutation detection in FGFR2 craniosynostosis syndromes

Human Genetics, 1997
Five autosomal dominant craniosynostosis syndromes (Apert, Crouzon, Pfeiffer, Jackson-Weiss and Crouzon syndrome with acanthosis nigricans) result from mutations in FGFR genes. Fourteen unrelated patients with FGFR2-related craniosynostosis syndromes were screened for mutations in exons IIIa and IIIc of FGFR2.
Hollway, G., Suthers, G., Haan, E., Thompson, E., David, D., Gecz, J., Mulley, J.   +6 more
openaire   +3 more sources

FGFR2: A pan-genomic target.

Journal of Clinical Oncology, 2019
3099 Background: FGFR2 genomic alterations (GA) have been described in a variety of solid tumors and emerged as biomarkers for investigational agents undergoing clinical trials. Methods: 201,766 primarily relapsed/refractory malignancies were evaluated with a hybrid-capture based sequencing assay Tumor mutational burden (TMB) was determined on 0.8-1 ...
Russell Madison, Ethan Sokol, Alexa Betzig Schrock, Adrienne Johnson, Dean Pavlick, Julia Andrea Elvin, Jo-Anne Vergilio, Nhu Ngo, Jonathan Keith Killian, Douglas I. Lin, Shakti Ramkissoon, Eric Allan Severson, Amanda Hemmerich, Daniel Duncan, Siraj Mahamed Ali, Prasanth Reddy, Kimberly McGregor, Brian Alexander, Vincent A. Miller, Jeffrey S. Ross   +19 more
openaire   +1 more source

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Nature, 2022
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko   +2 more
exaly  

OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2

Signal Transduction and Targeted Therapy, 2023
Chun-Ping Cui, Weiguo Zou, Lingqiang Zhang   +2 more
exaly  

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Cancer Discovery, 2022
Yuanli, Lei Shi, Patricia Greninger
exaly  

FGFR2

1995
M. Jaye, I. Lax, M. Mohammadi, J. Schlessinger   +3 more
openaire   +1 more source

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

The Lancet Gastroenterology and Hepatology, 2021
Milind Javle, Sameek Roychowdhury, Saeed Sadeghi   +2 more
exaly